- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Peskin Gives a Sneak Peek of His Session on Value-Based Contracting
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
Can you provide a sneak peek of some of your key talking points at Asembia?
I'll be talking about things that we've been doing and value-based cancer care, and certainly that covers a fairly broad expanse. We've been involved with a number of our oncology clinical partners at Horizon Blue Cross Blue Shield of New Jersey, with shared savings and moving into shared risk. We worked in non–small cell lung cancer, breast cancer, prostate, non-Hodgkin’s lymphoma, colorectal, among others. And so that's what I'll be highlighting.
We also had an oncology medical home model, which was partly benchmarked from Dr. [Barbara] McAneny’s work and Dr. [John] Sprandio’s work and had some elements of the OCM [Oncology Care Model]—we did not formally participate in the OCM, and we’re, as a company, in the very early stages and some of the preliminary discussions around Capitol Hill on the OCM. But we elected to go our own way with our own value payment models and oncology medical home.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
